Refractive adaptation and efficacy of occlusion therapy in untreated amblyopic patients aged 12 to 40 years.


Journal

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
ISSN: 1435-702X
Titre abrégé: Graefes Arch Clin Exp Ophthalmol
Pays: Germany
ID NLM: 8205248

Informations de publication

Date de publication:
Feb 2019
Historique:
received: 24 05 2018
accepted: 16 10 2018
revised: 11 09 2018
pubmed: 7 11 2018
medline: 20 2 2019
entrez: 7 11 2018
Statut: ppublish

Résumé

Since neurophysiological and clinical trials have shown evidence for plasticity in the adult visual system, the upper age limit for amblyopia treatment is not rigid. The aim of this study was to investigate the efficacy of occlusion therapy and refractive adaptation in untreated amblyopic patients 12 to 40 years of age. In a prospective study, all patients had full orthoptic and ophthalmic assessment including cycloplegic retinoscopy. Patients with a newly prescribed optical correction underwent an 18-week refractive adaptation. All patients were treated with occlusion for 3 h a day for 18 weeks. Acuity gain and responder rates (≥ 0.2 log units) were calculated. The rate of recurrence (visual acuity 9 months after end of the occlusion therapy; ≥ 0.2 log units) and the acuity gain after refractive adaptation were determined. Self-reported compliance to occlusion therapy was assessed. Median age of patients (n = 24) was 32.4 years (IQR 19.2). Best corrected visual acuity at start of occlusion therapy was 0.35 logMAR (IQR 0.5) and 0.30 (IQR 0.4) logMAR at the end of occlusion therapy, an acuity gain of 0.05 logMAR (P = 0.004). Six (25%) patients had an acuity gain of at least 0.2 logMAR units. Reading acuity was improved from 0.4 logMAR (IQR 0.4) to 0.3 logMAR (IQR 0.4) (P = 0.004). Visual acuity was stable 9 months after occlusion therapy. The acuity gain after 18 weeks of refractive adaptation was 0.05 logMAR (P = 0.238, n = 8). Acuity gain by correcting refractive errors was 0.25 logMAR (P = 0.006). Twenty-one (92%) of 24 patients achieved full recording in the calendar. Overall compliance was 17% (IQR 38). Only 5 out of 22 (23%) had acceptable compliance (≥ 50%) to occlusion therapy. Improvement of visual acuity was significantly better in patients with at least 50% compliance (P = 0.013). Compliance was worse in non-native patients than in native patients (P = 0.022). In adulthood, compliance to occlusion therapy is even more challenging than in children. Noncompliance is the main reason for treatment failure. Only a few patients with acceptable compliance to occlusion therapy had a small but significant improvement of visual acuity. The results suggest that some adults with amblyopia retain a degree of cortical plasticity. We found that untreated adult amblyopic patients did not wear optical correction on the amblyopic eye. The highest treatment benefit was achieved by correcting refractive errors prior to following period of refractive adaptation.

Identifiants

pubmed: 30397791
doi: 10.1007/s00417-018-4170-y
pii: 10.1007/s00417-018-4170-y
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

379-389

Références

Vision Res. 1999 May;39(9):1723-38
pubmed: 10343864
Strabismus. 1999 Jun;7(2):113-23
pubmed: 10420216
Curr Opin Neurobiol. 1999 Aug;9(4):480-6
pubmed: 10448162
Acta Ophthalmol Scand. 1999 Dec;77(6):673-6
pubmed: 10634561
Br J Ophthalmol. 2000 Jun;84(6):572-8
pubmed: 10837378
J Neurophysiol. 2000 Oct;84(4):1907-13
pubmed: 11024083
J Physiol. 2001 May 15;533(Pt 1):281-97
pubmed: 11351035
Lancet. 2002 Jun 22;359(9324):2129-30
pubmed: 12090976
Lancet. 2002 Aug 24;360(9333):597-602
pubmed: 12241931
J AAPOS. 2002 Oct;6(5):300-8
pubmed: 12381989
J Fr Ophtalmol. 2002 Sep;25(7):712-7
pubmed: 12399727
Graefes Arch Clin Exp Ophthalmol. 2003 Mar;241(3):176-80
pubmed: 12644939
Arch Ophthalmol. 2003 May;121(5):603-11
pubmed: 12742836
Nature. 2003 May 29;423(6939):534-7
pubmed: 12774121
Invest Ophthalmol Vis Sci. 2003 Aug;44(8):3278-81
pubmed: 12882770
Neuron. 2003 Dec 4;40(5):1023-9
pubmed: 14659100
J Pediatr Ophthalmol Strabismus. 2004 Mar-Apr;41(2):89-95
pubmed: 15089063
Invest Ophthalmol Vis Sci. 2004 Sep;45(9):3048-54
pubmed: 15326120
Strabismus. 2004 Sep;12(3):181-93
pubmed: 15370526
Graefes Arch Clin Exp Ophthalmol. 2005 Mar;243(3):278-80
pubmed: 15452721
J AAPOS. 2004 Oct;8(5):420-8
pubmed: 15492733
Br J Ophthalmol. 2004 Dec;88(12):1552-6
pubmed: 15548811
Invest Ophthalmol Vis Sci. 2005 Apr;46(4):1435-9
pubmed: 15790912
Arch Ophthalmol. 2005 Apr;123(4):437-47
pubmed: 15824215
Am J Med. 2005 May;118 Suppl 5A:27S-34S
pubmed: 15850551
Strabismus. 2005 Jun;13(2):93-106
pubmed: 16020365
Invest Ophthalmol Vis Sci. 2005 Sep;46(9):3152-60
pubmed: 16123414
Vision Res. 2006 Mar;46(5):739-50
pubmed: 16153674
Vision Res. 2006 Feb;46(4):506-26
pubmed: 16321418
J AAPOS. 2006 Feb;10(1):37-43
pubmed: 16527678
Invest Ophthalmol Vis Sci. 2006 Oct;47(10):4393-400
pubmed: 17003431
Korean J Ophthalmol. 2006 Sep;20(3):171-6
pubmed: 17004632
Graefes Arch Clin Exp Ophthalmol. 2007 Jun;245(6):811-6
pubmed: 17047980
Ophthalmology. 2006 Nov;113(11):2097-100
pubmed: 17074568
Am J Ophthalmol. 2007 Jan;143(1):54-60
pubmed: 17113556
Br J Ophthalmol. 2007 May;91(5):579-84
pubmed: 17124245
Vision Res. 2007 Jan;47(2):179-88
pubmed: 17126872
Klin Monbl Augenheilkd. 2007 Jan;224(1):40-6
pubmed: 17260318
Psychol Sci. 2007 Jan;18(1):88-94
pubmed: 17362383
Binocul Vis Strabismus Q. 2007;22(1):49-56
pubmed: 17417966
Arch Ophthalmol. 2007 May;125(5):655-9
pubmed: 17502505
Br J Ophthalmol. 2007 Nov;91(11):1450-1
pubmed: 17522151
BMJ. 2007 Oct 6;335(7622):707
pubmed: 17855283
Invest Ophthalmol Vis Sci. 2007 Nov;48(11):5332-8
pubmed: 17962490
Br J Ophthalmol. 2008 Feb;92(2):241-4
pubmed: 17993577
BMJ. 2008 Jan 5;336(7634):29-32
pubmed: 18087076
Curr Opin Neurobiol. 2008 Feb;18(1):101-7
pubmed: 18534841
Vision Res. 2008 Jul;48(15):1625-40
pubmed: 18547600
Invest Ophthalmol Vis Sci. 2008 Sep;49(9):3940-54
pubmed: 18765634
J Neurosci. 2008 Dec 24;28(52):14223-9
pubmed: 19109504
Nat Neurosci. 2009 May;12(5):549-51
pubmed: 19330003
Graefes Arch Clin Exp Ophthalmol. 2009 Oct;247(10):1401-8
pubmed: 19415317
Br J Ophthalmol. 2009 Nov;93(11):1499-503
pubmed: 19661070
Strabismus. 2009 Sep;17(3):107-16
pubmed: 20804358
Klin Monbl Augenheilkd. 2010 Oct;227(10):774-81
pubmed: 20963679
J Neurosci. 2010 Nov 10;30(45):14964-71
pubmed: 21068299
Graefes Arch Clin Exp Ophthalmol. 2011 Dec;249(12):1893-9
pubmed: 21399941
Invest Ophthalmol Vis Sci. 2011 Aug 17;52(9):6501-10
pubmed: 21693615
Strabismus. 2011 Sep;19(3):110-8
pubmed: 21870914
PLoS Biol. 2011 Aug;9(8):e1001135
pubmed: 21912514
Ophthalmic Physiol Opt. 2011 Nov;31(6):564-73
pubmed: 21981034
Annu Rev Neurosci. 2012;35:309-30
pubmed: 22462544
Curr Biol. 2013 Apr 22;23(8):R308-9
pubmed: 23618662
Strabismus. 2013 Jun;21(2):137-9
pubmed: 23713938
Invest Ophthalmol Vis Sci. 2013 Sep 17;54(9):6158-66
pubmed: 23882695
Saudi J Ophthalmol. 2012 Jul;26(3):305-7
pubmed: 23961010
Nature. 2013 Sep 26;501(7468):543-6
pubmed: 23975100
Vision Res. 2014 Oct;103:11-9
pubmed: 25130409
Vision Res. 2015 Sep;114:161-72
pubmed: 25676883
Sci Rep. 2015 Feb 26;5:8482
pubmed: 25719537
Invest Ophthalmol Vis Sci. 2015 Jun;56(6):4061-75
pubmed: 26114483
J Physiol. 2016 Jan 1;594(1):149-67
pubmed: 26449521
J Neurosci. 2016 Oct 26;36(43):11006-11012
pubmed: 27798181
Ophthalmic Physiol Opt. 2018 Mar;38(2):129-143
pubmed: 29356022
Am J Ophthalmol. 1988 Apr 15;105(4):337-47
pubmed: 3258733
Graefes Arch Clin Exp Ophthalmol. 1988;226(2):154-7
pubmed: 3360344
Ophthalmic Physiol Opt. 1987;7(4):461-7
pubmed: 3454923
Am J Ophthalmol. 1986 May 15;101(5):515-23
pubmed: 3706455
Cancer. 1986 Sep 1;58(5):1179-84
pubmed: 3731045
Diabetes Care. 1980 Sep-Oct;3(5):594-8
pubmed: 7002514
Klin Monbl Augenheilkd. 1982 Mar;180(3):210-5
pubmed: 7078011
Br J Ophthalmol. 1995 Jun;79(6):585-9
pubmed: 7626576
Proc Natl Acad Sci U S A. 1996 Jun 25;93(13):6830-4
pubmed: 8692904
Neurosci Lett. 1997 Apr 11;225(3):173-6
pubmed: 9147398
J Neurosci. 1998 Aug 15;18(16):6411-24
pubmed: 9698332

Auteurs

Brigitte Simonsz-Tóth (B)

Department of Ophthalmology, Haaglanden Medical Centre, The Hague, The Netherlands. btoth@bluewin.ch.

Maurits V Joosse (MV)

Department of Ophthalmology, Haaglanden Medical Centre, The Hague, The Netherlands.

Dorothea Besch (D)

Department of Ophthalmology, Eberhard Karls University, Tübingen, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH